Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 7 of 7
Jan 13, 2026At JPM 2026, Nvidia unveiled significant partnerships with leading pharma and life sciences companies including Eli Lilly and Thermo Fisher, illustrating its ambition to become a critical technology provider underpinning AI innovation in drug discovery and research laboratories worldwide.
Jan 12, 2026Both Anthropic and OpenAI are expanding their large language models into the healthcare sector, employing different strategies to integrate AI tools that address a variety of healthcare needs. Understanding their platforms’ design and targeted users offers insights into the evolving role of AI in medicine.
Jan 11, 2026The healthcare AI landscape has witnessed rapid innovation, with personalized health information tools becoming increasingly vital. Microsoft's initial foray with an AI product integrating deeply in health records has not seen recent developments, raising questions about strategic execution in this competitive domain.
Jan 8, 2026The new offering represents a significant development in AI-driven healthcare interactions, reflecting regulatory shifts as the FDA pursues a deregulatory stance on AI and digital health tools.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.